The association of cardioprotective medications with pneumonia-related outcomes

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Wu, Albert ^a,b   Good, Chester ^d,e   Downs, John R ^a,b   Fine, Michael J ^d,e   Pugh, Mary Jo V ^a,c   Anzueto, Antonio ^a,b   Mortensen, Eric M ^f,g  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART PROTECTION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; POPULATION RESEARCH; RETROSPECTIVE STUDY; CARDIOVASCULAR DISEASES; COMPLICATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PNEUMONIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84900333564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085797     Document Type: Article

References (33)

1. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B (2010) Deaths: Final Data for 2007. National Vital Statistics Reports 58.
2. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A (2010) National Hospital Discharge Survey: 2007 summary. National health statistics reports: 1-20, 24.
3. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ (2005) Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 294: 2712-2719. (Pubitemid 41770100)
4. Musher DM, Rueda AM, Kaka AS, Mapara SM (2007) The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 45: 158-165. (Pubitemid 47041005)
5. Perry TW, Pugh MJ, Waterer GW, Nakashima B, Orihuela CJ, et al. (2011) Incidence of cardiovascular events after hospital admission for pneumonia. The American Journal of Medicine 124: 244-251.
6. Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, et al. (2008) Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 47: 182-187. (Pubitemid 351920618)
7. Mandal P, Chalmers JD, Choudhury G, Akram AR, Hill AT (2011) Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM : monthly journal of the Association of Physicians 104: 489-495.
8. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, et al. (2008) Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 31: 611-617.
9. Mortensen EM, Restrepo MI, Anzueto A, Pugh J (2005) The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 6: 82.
10. Nakashima B, Restrepo MI, Anzueto A, Mortensen EM (2010) The Potential Role of Statins in Pneumonia. Current Respiratory Medicine Reviews 6: 1-7.
11. Brown SH, Lincoln MJ, Groen PJ, Kolodner RM (2003) VistA-U.S. Department of Veterans Affairs national-scale HIS. Int J Med Inform 69: 135-156. (Pubitemid 38373274)
12. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, et al. (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278: 2080-2084. (Pubitemid 28016230)
13. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47: 1245-1251. (Pubitemid 24361532)
14. Corrales-Medina VF, Madjid M, Musher DM (2010) Role of acute infection in triggering acute coronary syndromes. The Lancet Infectious Diseases 10: 83-92.
15. Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, et al. (2009) Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 88: 154-159.
16. Thomsen RW, Kasatpibal N, Riis A, Norgaard M, Sorensen HT (2008) The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J Gen Intern Med 23: 1407-1413.
17. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C (1995) Patterns of cytokine expression in community-acquired pneumonia. Chest 107: 1342-1349.
18. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S (1999) Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 54: 51-55. (Pubitemid 29103752)
19. Mendall MA, Patel P, Asante M, Ballam L, Morris J, et al. (1997) Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78: 273-277. (Pubitemid 27431736)
20. Wang G, Burczynski F, Hasinoff B, Zhong G (2002) Infection of myocytes with chlamydiae. Microbiology 148: 3955-3959. (Pubitemid 36097457)
21. Antonarakis ES, Wung PK, Durand DJ, Leyngold I, Meyerson DA (2006) An atypical complication of atypical pneumonia. Am J Med 119: 824-827. (Pubitemid 44415622)
22. Armengol S, Domingo C, Mesalles E (1992) Myocarditis: a rare complication during Legionella infection. Int J Cardiol 37: 418-420.
23. Kuiken T, Taubenberger JK (2008) Pathology of human influenza revisited. Vaccine 26 Suppl 4: D59-66.
24. Fillon S, Soulis K, Rajasekaran S, Benedict-Hamilton H, Radin JN, et al. (2006) Platelet-activating factor receptor and innate immunity: uptake of gram-positive bacterial cell wall into host cells and cell-specific pathophysiology. J Immunol 177: 6182-6191. (Pubitemid 44628836)
25. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294: 1043-1046. (Pubitemid 30666857)
26. Dagenais NJ, Jamali F (2005) Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 25: 1213-1229. (Pubitemid 41244813)
27. Hothersall E, McSharry C, Thomson NC (2006) Potential therapeutic role for statins in respiratory disease. Thorax 61: 729-734. (Pubitemid 44211783)
28. Mancini GB, Khalil N (2005) Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med 28: 118-126. (Pubitemid 40978706)
29. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, et al. (2002) Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 166: 646-650. (Pubitemid 34971844)
30. Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, et al. (2006) Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 34: 1001-1006.
31. Liu CF, Bryson CL, Burgess JF, Jr., Sharp N, Perkins M, et al. (2012) Use of outpatient care in VA and Medicare among disability-eligible and age-eligible veteran patients. BMC Health Serv Res 12: 51.
32. Kircher T, Nelson J, Burdo H (1985) The autopsy as a measure of accuracy of the death certificate. N Engl J Med 313: 1263-1269. (Pubitemid 16217049)
33. Lloyd-Jones DM, Martin DO, Larson MG, Levy D (1998) Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med 129: 1020-1026. (Pubitemid 29005825)